Valuation: CSL Limited

Market Cap 44.59B 38.69B 36.23B 33.14B 62.57B 4,248B 63.39B 424B 166B 2,122B 167B 164B 7,064B P/E 2026 *
-59.8x
P/E 2027 * 32.8x
Enterprise Value 53.3B 46.26B 43.31B 39.62B 74.8B 5,078B 75.78B 507B 199B 2,537B 200B 196B 8,444B EV / Sales 2026 *
3.47x
EV / Sales 2027 * 3.37x
Free-Float
99.3%
Yield 2026 *
3.07%
Yield 2027 * 3.14%
1 day-0.13%
1 week+7.42%
Current month+7.42%
1 month+6.63%
3 months+8.35%
6 months-26.71%
Current year-23.43%
1 week 121.87
Extreme 121.87
133.35
1 month 113.75
Extreme 113.75
133.35
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
273.45
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap.
23/2/26 Free

Director

263 0.0001%
23/2/26 Free 512 0.0001%
19/2/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%+7.42%-50.22%-49.58% 44.59B
+0.46%+4.57%+39.09%+0.74% 77.1B
+1.56%+2.56%+23.90%+186.04% 49.43B
+1.54%-0.85%-4.49%+23.71% 49.27B
-0.17%-0.79%+59.49%-23.29% 30.48B
-1.19%-3.75%+52.45%+86.04% 24B
-4.26%-7.01%+101.65%-50.22% 21.5B
+4.29%+9.40%+3.77%+226.51% 20.18B
+1.66%-3.87%+65.11%+123.52% 16.29B
+0.99%+0.80%+84.78%+164.96% 16.19B
Average +1.21%+0.05%+37.55%+68.84% 34.9B
Weighted average by Cap. +0.99%+1.45%+27.22%+50.82%

Financials

2026 *2027 *
Net sales 15.38B 13.35B 12.5B 11.43B 21.58B 1,465B 21.86B 146B 57.38B 732B 57.75B 56.49B 2,436B 15.59B 13.53B 12.67B 11.59B 21.88B 1,485B 22.16B 148B 58.16B 742B 58.53B 57.26B 2,469B
Net income -967M -839M -786M -719M -1.36B -92.08B -1.37B -9.19B -3.61B -46.01B -3.63B -3.55B -153B 1.18B 1.03B 963M 880M 1.66B 113B 1.68B 11.26B 4.42B 56.38B 4.45B 4.35B 188B
Net Debt 8.71B 7.56B 7.08B 6.48B 12.23B 830B 12.39B 82.85B 32.51B 415B 32.72B 32.01B 1,381B 7.98B 6.92B 6.48B 5.93B 11.19B 760B 11.34B 75.83B 29.76B 380B 29.95B 29.3B 1,264B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
07/08/26 $132.19 -0.13% 779,357
06/08/26 $132.36 +1.30% 1,125,931
05/08/26 $130.66 +1.42% 1,118,928
04/08/26 $128.83 +3.64% 1,133,249
03/08/26 $124.30 +1.01% 709,405
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
93.11USD
Average target price
96.79USD
Spread / Average Target
+3.96%

Quarterly revenue - Rate of surprise